



SYNTHESIS AND BIOLOGICAL EVALUATION OF MORPHOLINE AND SALICYLAMIDE NUCLEUS BASED DERIVATIVES.

Loganathan Velupillai¹, Prashant P Dixit², M.S. Shingare¹ & D.V. Mane*¹

¹Department of Chemistry, Dr. Babasaheb Ambedkar Marathwada University, Aurangabad,
Maharashtra, India- 431004.

²Department of Microbiology, Dr. Babasaheb Ambedkar Marathwada University,
Aurangabad, Sub Campus, Osmanabad, Maharashtra, India- 431004.

Article Received on 15/02/2015

Article Revised on 07/03/2015

Article Accepted on 28/03/2015

***Correspondence for**

Author

Loganathan Velupillai

Department Of Chemistry,
Dr. Babasaheb Ambedkar
Marathwada University,
Aurangabad, Maharashtra,
India- 431004.

ABSTRACT

Morpholine backbone is essential in different pharmacologically active synthetic compounds. Present work is synthesis of novel morpholine and salicylamide nucleus based compounds such as 3-amino-2, 2-dimethylpropyl 2-(2-(2-morpholinoethylcarbonyl)phenoxy)acetate and their derivatives (6 L – 6 R). The compounds were synthesized in multistep reaction with more efficient process. Starting materials are

commercially available and is also available from Sigma-Aldrich. The chemical structures of the synthesized compounds were confirmed by means of ¹HNMR and mass spectral data. High yield and high purity indicates lack of side reaction and by product. The synthesized compounds were then examined for their antibacterial and antifungal activities. Some of them were found to possess good antibacterial and antifungal activity.

KEYWORDS: Morpholine, Salicylamide, Salicylic acid, Antibacterial, Antifungal Activity.

INTRODUCTION

Though there are many of active compounds developed for functionalized morpholine. Still there is scope for synthesis of new compounds to built morpholine ring system & it found to be among the most efficient for achieving useful transformations in to morpholine backbone and their derivatives later on. Nitrogen and oxygen containing heterocyclic compounds like morpholine^[1] and substituted morpholine^[2-5] are very important building blocks in medicinal chemistry^[6] field. So the morpholine derivatives are extensively very essential in the drug

discovery research, which stimulate research activity in the field of the broad spectrum of biological activity^[7] study. After the literature survey that many morpholine derivative molecule are shows very good biological activity in different therapeutic area such as antibacterial^[8], antiviral, anticancer, antimicrobial, antidiabetic, anti-Inflammatory, antimalarial, antifungal^[9], Antiemetic etc.




Figure 1: Marketed drugs containing a direct linked morpholine ring.




Figure 2: Clinical and preclinical drugs having a fused morpholine ring.

Hence, in the present study, we have considered chemical moiety which gives sounder biological profile like salicylic acid^[10-12], 3-amino-2,2-dimethylpropan-1-ol^[13-15] and 2-chloroethanamine hydrochloride^[16-18]. The salicylamide^[19-21] was introduced in our moiety considering the better biological activity in vaster range of therapeutic field. Suitable conditions were used for functional group protection^[22] and de-protection. Here some new substituted morpholine like 3-amino- 2, 2 - dimethylpropyl 2-(2-(2-

morpholinoethylcarbonyl)phenoxy)acetate and their derivatives have been synthesized. The prepared substituted morpholine and their derivatives are very useful building blocks in medicinal chemistry. The chemical structures of the synthesized compounds were confirmed by spectroscopic methods like ^1H NMR and mass spectral data.

MATERIALS AND METHODS

All the reagents and solvents were used as obtained from the supplier or recrystallized/redistilled as necessary. The moiety Ethyl cyanoacetate, salicylic acid, 3-amino-2,2-dimethylpropan-1-ol and 2-chloroethanamine hydrochloride is commercially available and is also in Sigma Aldrich. This can be also synthesized as per reported literature. Melting points were recorded on open capillary melting point apparatus and are uncorrected. Mass spectra were recorded on 'LCMS-QP2010s' instrument by direct injection method. Nuclear Magnetic Resonance spectra (^1H NMR) Were recorded in DMSO-d_6 & CDCl_3 on Bruker advance spectrometer at 400MHz using Tetramethylsilane (TMS) as internal standard and the chemical shift (δ) are reported in parts per million. The purity of the synthesized compounds was checked by Thin Layer Chromatography, Merck pre-coated plates (silica gel 60 F254) were visualized with UV light. Fungus Culture: *Candida* sp. Gram-positive microorganisms: *Staphylococcus aureus*, *Staphylococcus albus*, *Streptococcus faecalis*, *Bacillus* sp and Gram-negative microorganisms: *Klebsiella pneumoniae*, *Escherichia coli*, *Pseudomonas* sp, *Proteus* sp were used for biological activity.

Antimicrobial Activity: The antimicrobial activity of all synthesized compounds (6 L – 6 R) were screened against different standard organism obtained from the American type of cell culture collection, including *Staphylococcus aureus*, *Escherichia coli* and *Pseudomonas* sp. Agar diffusion technique at the concentration level of 5 μg molar was applied. Ciprofloxacin was used as reference compounds for antibacterial activities.

The antimicrobial activity of all the newly synthesized compounds were determined by well plate method in nutrient agar (Hi-media) was used for antibacterial activity. The antibacterial activity of the test compounds was assayed against gram-positive and gram-negative by Cup plate method. The compounds were tested at a concentration of a 100 $\mu\text{g}/\text{ml}$ were prepared in dimethylformamide (DMF). The Petri dishes used for antibacterial screening were incubated at 37 ± 1 for 24h; the diameters of zone of inhibition (mm) surroundings each of the wells recorded. The results were compared Ciprofloxacin of a 100 $\mu\text{g}/\text{ml}$ concentration (cacic, M et al., 2006).

Antifungal Activity: The antifungal activity of all synthesized compounds (6 L – 6 R) screened against *Candida* sp in DMF by poisoned food technique. Fluconazole was employed as standard drug during the test procedures as references. Potato dextrose agar (PDA) Media were prepared and about 15ml of PDA was poured into each Petri plate allowed to solidify 5mm disc of seven-day-old culture of the test fungi was placed at the centre of the Petri plates and incubated at 26°C for 7 days. After incubation, the percentage inhibition was measured and three replicates were maintained for each treatment.

EXPERIMENTAL







Figure 3: Synthesis of 3-amino-2, 2-dimethylpropyl 2-(2-(2-morpholinoethylcarbonyl) phenoxy)acetate and their derivatives.

Table 1: Physical data of synthesized compounds (6 L – 6 R).

Code	-R	Molecular Formula	M.wt	M.P (°C)	% Yield
6 L		C ₂₀ H ₃₁ N ₃ O ₅	393.47	72-75	94
6 M		C ₂₂ H ₃₃ N ₃ O ₆	435.51	146-149	85
6 N		C ₂₇ H ₃₅ N ₃ O ₆	497.58	175-178	82
6 O		C ₂₅ H ₃₉ N ₃ O ₆	477.59	137-140	78

6 P		$C_{23}H_{35}N_3O_7$	465.53	121-124	76
6 Q		$C_{27}H_{36}N_4O_6$	512.59	191-194	86
6 R		$C_{25}H_{39}N_3O_7$	493.59	134-137	88

Preparation of tert-butyl 2-chloroethylcarbamate (B): The BOC anhydride (20.7g, 94mmol) was added drop-wise to the solution of sodium hydrogen carbonate (18.1g, 215mmol) and 2-Chloroethylamine hydrochloride (10g, 86mmol) in water (100ml) at room temperature. The resulting suspension was stirred at room temperature for 4hr. After completion of reaction, the reaction was extracted with 2x40ml of ethyl acetate, dried with sodium sulfate and distilled out solvent completely. Yielded the titled product (B) as yellow oil.

Preparation of tert-butyl 2- morpholino ethylcarbamate (C): The morpholine (6.4g, 73mmol) was added to the solution of compound (B) (12g, 66mmol) Triethylamine (8.09g, 88mmol), Potassium iodide (1.1g, 6mmol) in $CHCl_3$ (60ml) and the mixture was stirred for 8hr at reflux. After completion of reaction, the reaction mass cooled to room temperature and washed with water (2x40ml), dried with sodium sulfate and distilled out solvent completely. The residue was suspended in hexane (60ml), stirred for 1hr, filtered and washed with hexane (20ml), after drying yielded the titled product (C) as white solid.

Preparation of 2-morpholinoethanamine trifluoroacetic acid salt (D): The trifluoroacetic acid (24ml) was added slowly to the solution of compound (C) (12g, 52mmol) in dichloromethane (60ml) at $0^\circ C$ and the mixture was stirred for 2 hour at $0^\circ C$. After completion of reaction, the solution was evaporated in vacuum and the residue was suspended in acetone (60ml), stirred for 1hr, filtered and washed with hexane (20ml), after drying Yielded the titled product (D) Trifluoroacetic acid salt as off-white solid.

Preparation of 2-hydroxy-N-(2-Morpholinoethyl) benzamide (E): The compound (D) (11g, 45mmol), salicylic acid (5.27g, 40 mmol), EDC.HCl (11.18g, 58mmol), HOBT (6.08g, 45mmol) and N, N-Diisopropylethylamine (14.55g 112mmol) was added to the DMF (100ml). The mixture was stirred for 4 hour at room temperature. After completion of

reaction, the reaction mass poured into cold water (400ml), stirred at room temperature for 2hr. Filtered and washed with water (20ml), after drying yielded the titled product (E) as off-white solid.

Preparation of Ethyl-2-cyano-2-methyl propanoate (G): The methyl iodide (56.47g, 0.39mol) was added slowly to the solution of cesium carbonate (95g, 0.29mol), Ethyl cyanoacetate (F) (15g, 0.13mol), in N,N –Dimethylformamide (45ml) at 0°C and the mixture was stirred for 4hr at room temperature. After completion of reaction, the reaction mass poured into 200ml of cold water extracted with 2x50 ml of ethyl acetate, dried with sodium sulfate. Distilled out solvent completely. Pure product isolated by doing high vacuum (10mm) distillation, vapor temperature 50-60°C, oil bath temperature 75°C yielded the titled product (G) as colorless oil.

Preparation of 3-amino-2,2-dimethyl propan-1-ol (H): The compound (G) (9g, 63mmol) in 45ml of tetrahydrofuran was added to the solution of Lithium Aluminium Hydride (3.63g, 95mmol) in tetrahydrofuran (45ml) at 0°C and the mixture was stirred for 6 hour at room temperature. After completion of reaction, the reaction was quenched with wet sodium sulfate. The reaction mass filtered through celite bed washed with tetrahydrofuran 20 ml. The filtrate was distilled out completely. Yielded the titled product (H) as white solid.

Preparation of Benzyl (3-hydroxy-2,2-dimethylpropyl)carbamate (I)

The benzylchloroformate (50% in Toluene) (17.82 ml, 53mmol) was added to the solution of compound (H) (5g, 48mmol), sodium bicarbonate (6.1g, 72mmol) in water (50ml) and the mixture was stirred for 1 hour at room temperature. After completion of reaction, the reaction was extracted with 2x20ml of ethyl acetate, dried with sodium sulfate and distilled out completely. The solid was re-crystallized by n-Pentane (20ml). Yielded the titled product (I) as off-white solid.

Preparation of Benzyl 3-(2-chloroacetoxy)-2,2-dimethylpropylcarbamate (J): The chloroacetyl chloride (4.53g, 40mmol) was added to the solution compound (I) (8g, 33mmol) and triethylamine (5.06g, 50mmol) in dichloromethane (80ml) at 0°C. The mixture was stirred for 4 hr at 0°C. After completion of reaction, the solution was evaporated in vacuum and the residue was suspended in 120ml of ethyl acetate and washed with 2x40ml of 10% sodium bicarbonate solution. The organic layer dried with sodium sulfate and evaporated the

solvent. Pure product isolated by flash column chromatography eluted with 10% ethyl acetate in hexane yielded the titled product (**J**) as light brown solid.

Preparation of Benzyl 3-(2-(2-(2-morpholinoethylcarbamoyl)phenoxy)acetoyloxy)-2,2-dimethyl propylcarbamate (K): The Compound (J) (5g, 19mmol) was added to the solution compound of potassium tert butoxide (3.36g, 29mmol) in N,N-Dimethylformamide (40ml) and the mixture was stirred for 15 minutes at room temperature. Then charged compound (h) (6.26g, 19mmol) lot wise and the mixture was stirred for 4 hour at room temperature. After completion of reaction, the reaction mass slowly poured into 200ml of cold water and stirred for 2 hr. Filtered and washed with water (20ml) after drying yielded the titled product (K) as off-white solid.

Preparation of 3-amino-2,2-dimethylpropyl 2-(2-(2-morpholinoethylcarbamoyl)phenoxy)acetate (6 L): The methanol (60ml), Compound (K) (6g, 11mmol) and 10% Pd-C (0.6gm) catalyst was added into the hydrogenation Parr shaker reactor. 30 PSI of hydrogen gas applied and the mixture was shaken for 6 hour. After completion of reaction, the reaction mass filtered through celite bed washed with methanol 20ml. The Filtrate was distilled out completely. Yielded the titled product (6 L) as white solid.

Preparation of 3-acetamido-2,2-dimethylpropyl 2-(2-(2-morpholinoethylcarbamoyl)phenoxy) acetate (6 M): The Acetyl chloride (79.79mg, 1.01mol) was added to the solution of compound (6 L) (400mg, 1.01mol), N,N-Diisopropyl ethylamine (144.52mg, 1.11mol) in dichloromethane (4ml) at 0°C and the mixture was stirred for 2 hour at 0°C. After completion of reaction, the solution was evaporated in vacuum and the residue was suspended in 4ml of ethyl acetate and washed with 2x4ml of 10% sodium bicarbonate solution. The organic layer dried with sodium sulfate and slowly poured into 8 ml of hexane at room temperature, stirred for 2 hr at room temperature. Filtered and washed with hexane (2ml), after drying yielded the titled product (6 M) as white solid.

Preparation of 3-(benzamido)-2,2-dimethylpropyl 2-(2-(2-morpholinoethylcarbamoyl)phenoxy) acetate (6 N): The Benzoyl chloride (142.9mg, 1.01mol) was added to the solution of compound (6 L) (400g, 1.01mole), N,N-Diisopropyl ethylamine (144.52mg, 1.11mol) in dichloromethane (4ml) at 0°C and the mixture was stirred for 2 hour at 0°C. After completion of reaction, the solution was evaporated in vacuum and the residue was suspended in 4ml of ethyl acetate and washed with 2x4ml of 10% sodium bicarbonate solution. The organic layer

dried with sodium sulfate and slowly poured into 8 ml of hexane at room temperature. Stirred for 2 hr at room temperature. Filtered and washed with hexane (2ml), after drying yielded the titled product (6 N) as white solid.

Preparation of 2,2-dimethyl-3-(pivalamido)propyl 2-(2-(2-morpholinoethylcarbamoyl) phenoxy) acetate (6 O): The pivaloyl chloride (122.58mg, 1.01mol) was added to the solution of compound (6 L) (400mg, 1.01mol), N,N-Diisopropyl ethylamine (144.52mg, 1.11mol) in dichloromethane (4ml) at 0°C and the mixture was stirred for 2 hour at 0°C. After completion of reaction, the solution was evaporated in vacuum and the residue was suspended in 4ml of ethyl acetate and washed with 2x4ml of 10% sodium bicarbonate solution. The organic layer dried with sodium sulfate and slowly poured into 8 ml of hexane at room temperature. Stirred for 2 hr at room temperature. Filtered and washed with hexane (2ml), after drying yielded the titled product (6 O) as white solid.

Preparation of Ethyl 3-(2-(2-(2-morpholinoethylcarbamoyl) phenoxy) acetoxy)-2,2-dimethyl propylcarbamate (6 P): The Ethyl chloroformate (108.52mg, 1.01mol) was added to the solution of compound (6 L) (400mg, 1.01mol), N,N-Diisopropyl ethylamine (144.52mg, 1.11mole) in dichloromethane (4ml) at 0°C and the mixture was stirred for 2 hour at 0°C. After completion of reaction, the solution was evaporated in vacuum and the residue was suspended in 4ml of ethyl acetate and washed with 2x4ml of 10% sodium bicarbonate solution. The organic layer dried with sodium sulfate and slowly poured into 8 ml of hexane at room temperature. Stirred for 2 hr at room temperature. Filtered and washed with hexane (2ml), after drying yielded the titled product (6 P) as white solid.

Preparation of 2,2-dimethyl-3-(3-Phenylureido)propyl 2-(2-(2-morpholinoethylcarbamoyl) phenoxy) acetate (6 Q): The phenyl isocyanate (121.09mg, 1.01mol) was added slowly to the solution of compound (6 L) (400mg, 4mol) in dichloromethane (4ml) at 0°C and the mixture was stirred for 1 hour. After completion of reaction, the reaction was evaporated in vacuum and the residue was suspended in 4ml of ethyl acetate and washed with 2x4ml of water. The organic layer dried with sodium sulfate and distilled out completely. Yielded the titled product (6 Q) as white solid.

Preparation of Isobutyl 3-(2-(2-(2-morpholinoethylcarbamoyl) phenoxy) acetoxy)-2,2-dimethylpropylcarbamate (6 R): The Isobutyl chloroformate (138.84 mg, 1.01mol) was added to the solution of compound (6 L) (400mg, 1.01 mol), N,N-Diisopropyl ethylamine

(144.52mg, 1.11mol) in dichloromethane (4ml) at 0°C and the mixture was stirred for 2 hour at 0°C. After completion of reaction, the solution was evaporated in vacuum and the residue was suspended in 4ml of ethyl acetate and washed with 2x4ml of 10% sodium bicarbonate solution. The organic layer dried with sodium sulfate and slowly poured into 8 ml of hexane at room temperature. Stirred for 2 hr at room temperature. Filtered and washed with hexane (2ml), after drying yielded the titled product (6 R) as white solid.

RESULTS AND DISCUSSION

The results are obtained from various spectral data are results discussed below.

Preparation of tert-butyl 2-chloroethylcarbamate (B): A oily mass 13.5g (Yield 87%). M.W: 179.6; Mol For: C₇H₁₄ClNO₂; LC-MS (m/z): 180.1 (M+1); ¹HNMR (400MHz, CDCl₃): δ 7.62 (s, 1H), 3.71-3.73 (t, 2H), 3.32-3.35 (t, 2H), 1.36 (s, 9H).

Preparation of tert-butyl 2- morpholino ethylcarbamate (C): A white solid 14g (Yield 91%). M.W: 230.3; Mol For: C₁₁H₂₂N₂O₃; LC-MS (m/z): 231.2 (M+1); ¹HNMR (400MHz, DMSO-d₆): δ 6.65 (s, 1H), 3.53-3.55 (t, 4H), 3.00-3.05 (m, 2H), 2.27-2.34 (m, 6H), 1.37 (s, 9H).

Preparation of 2-morpholinoethanamine trifluoroacetic acid salt (D): A off-white solid 12g (Yield 94%). M.W: 244.21; Mol For: C₈H₁₅F₃N₂O₃; LC-MS (m/z): 131.1 (M+1); ¹HNMR (400MHz, DMSO-d₆): δ 3.54-3.56 (t, 4H), 2.58-2.61 (t, 2H), 2.33 (s, 4H), 2.25-2.28 (t, 2H), 1.22-1.68 (bs, 2H).

Preparation of 2-hydroxy-N-(2-Morpholinoethyl) benzamide (E): A off-white solid 9g (Yield 80%). M.W: 250.29; Mol For: C₁₃H₁₈N₂O₃; LC-MS (m/z): 251.2 (M+1); ¹HNMR (400MHz, DMSO-d₆): δ 12.42 (s, 1H), 8.82 (s, 1H), 7.81-7.84 (d, 1H), 7.37-7.41 (t, 1H), 6.87-6.91 (t, 2H), 3.58-3.60 (t, 4H), 3.41-3.46 (m, 2H), 2.55-2.26 (t, 2H).

Preparation of Ethyl-2-cyano-2-methyl propanoate (G): colorless oil 14g (Yield 75%). M.W: 141.16; Mol For: C₇H₁₁NO₂; ¹HNMR (400MHz, DMSO-d₆): δ 4.39-4.44 (q, 2H), 1.76 (s, 6H), 1.46-1.49 (t, 3H).

Preparation of 3-amino-2,2-dimethyl propan-1-ol (H): A white solid 6.2g (Yield 94%). M.W: 103.16; Mol For: C₅H₁₃NO; LC-MS (m/z): 104.0 (M+1); ¹HNMR (400MHz, CDCl₃): δ 3.51 (s, 2H), 2.73 (s, 2H), 2.68 (s, 2H), 0.90 (s, 6H).

Preparation of Benzyl (3-hydroxy-2,2-dimethylpropyl)carbamate (I): A off-white solid 8.5g (Yield 74%). M.W: 237.29; Mol For: C₁₃H₁₉NO₃; LC-MS (m/z): 238.2 (M+1); ¹HNMR (400MHz, DMSO-d₆): δ 7.29-7.38 (m, 5H), 7.13-7.16 (t, 1H), 5.02 (s, 2H), 4.42 (s, 1H), 3.08 (s, 2H), 2.87-2.89 (d, 2H), 0.75 (s, 6H).

Preparation of Benzyl 3-(2-chloroacetoxy)-2,2-dimethylpropylcarbamate (J): A brown solid 7g (Yield 67%). M.W: 313.77; Mol For: C₁₅H₂₀ClNO₄; LC-MS (m/z): 314.2 (M+1); ¹HNMR (400MHz, CDCl₃): δ 7.35 (s, 5H), 5.08 (s, 2H), 4.08 (s, 2H), 3.95 (s, 2H), 3.10-3.11 (d, 2H), 0.94 (s, 6H).

Preparation of Benzyl 3-(2-(2-(2-morpholinoethylcarbamoyl)phenoxy)acetoxy)-2,2-dimethyl propylcarbamate (K): A off-white solid 7g (Yield 66%). M.W: 527.60; Mol For: C₂₈H₃₇N₃O₇; LC-MS (m/z): 528.5 (M+1); ¹HNMR (400MHz, DMSO-d₆): δ 8.49 (s, 1H), 7.87-7.89 (d, 2H), 7.31-7.44 (m, 6H), 7.07-7.15 (m, 2H), 5.01 (s, 4H), 3.85 (s, 2H), 3.54-3.56 (s, 4H), 3.41-3.43 (q, 2H), 2.91-2.92 (d, 2H), 2.46-2.47 (d, 2H), 2.39 (s, 4H), 0.81 (s, 6H).

Preparation of 3-amino-2,2-dimethylpropyl 2-(2-(2-morpholinoethylcarbamoyl)phenoxy)acetate (6 L): A white solid 4.2g (Yield 94%). M.W: 393.47; Mol For: C₂₀H₃₁N₃O₅; LC-MS (m/z): 394.4 (M+1); ¹HNMR (400MHz, DMSO-d₆): δ 8.68 (s, 1H), 7.69-7.71 (d, 1H), 7.43-7.47 (t, 1H), 7.04-7.09 (q, 2H), 4.73 (s, 2H), 4.47-4.50 (t, 2H), 3.55-3.57 (t, 4H), 3.37-3.42 (d, 2H), 3.01-3.06 (dd, 4H), 2.45-2.47 (m, 2H), 2.40 (s, 4H), 0.73 (s, 6H).

Preparation of 3-acetamido-2,2-dimethylpropyl 2-(2-(2-morpholinoethylcarbamoyl)phenoxy) acetate (6 M): A white solid 376mg (Yield 85%). M.W: 435.51; Mol For: C₂₂H₃₃N₃O₆; LC-MS (m/z): 436.4 (M+1); ¹HNMR (400MHz, CDCl₃): δ 7.83 (s, 1H), 7.71-7.73 (d, 1H), 7.42-7.46 (t, 1H), 7.09-7.11 (t, 1H), 6.95-6.97 (d, 1H), 4.76 (s, 2H), 3.68-3.84 (m, 6H), 3.55-3.59 (q, 2H), 3.20-3.22 (d, 2H), 2.53-2.63 (d, 6H), 2.03 (s, 2H), 0.86 (s, 6H).

Preparation of 3-(benzamido)-2,2-dimethylpropyl 2-(2-(2-morpholinoethylcarbamoyl)phenoxy) acetate (6 N): A white solid 415mg (Yield 82%). M.W: 497.58; Mol For: C₂₇H₃₅N₃O₆; LC-MS (m/z): 498.4 (M+1); ¹HNMR (400MHz, CDCl₃): δ 8.65 (s, 1H), 8.17 (s, 1H), 7.82-7.88 (m, 3H), 7.39-7.43 (t, 2H), 6.93-7.10 (m, 4H), 4.69 (s, 2H), 3.71-3.95 (m, 6H), 3.12-3.19 (m, 4H), 2.81-2.89 (d, 3H), 0.86 (s, 6H).

Preparation of 2,2-dimethyl-3-(pivalamido)propyl 2-(2-(2-morpholinoethylcarbamoyl) phenoxy) acetate (6 O): A white solid 379mg (Yield 78%). M.W: 477.59; Mol For: C₂₅H₃₉N₃O₆; LC-MS (m/z): 478.4 (M+1); ¹HNMR (400MHz, CDCl₃): δ 7.83 (s, 1H), 7.28-7.44 (d, 2H), 7.14-7.18 (t, 1H), 6.79-6.83 (t, 1H), 6.52-6.54 (d, 1H), 4.46 (s, 2H), 3.84-4.02 (m, 4H), 3.44-3.48 (m, 4H), 3.24-3.35 (m, 4H), 2.98-3.02 (s, 2H), 1.00 (s, 9H), 0.86 (s, 6H).

Preparation of Ethyl 3-(2,(2-(2-morpholinoethylcarbamoyl) phenoxy) acetoyloxy)-2,2-dimethyl propylcarbamate (6 P): A white solid 360mg (Yield 76%). M.W: 465.53; Mol For: C₂₃H₃₅N₃O₇; LC-MS (m/z): 466.4 (M+1); ¹HNMR (400MHz, DMSO-d₆): δ 7.63-7.66 (s, 1H), 7.32-7.43 (m, 2H), 6.99-7.04 (m, 2H), 4.49-4.56 (m, 3H), 3.87-3.96 (m, 4H), 3.51 (s, 4H), 3.01-3.07 (dd, 4H), 2.40 (d, 4H), 0.84-0.87 (t, 3H), 0.73 (s, 6H).

Preparation of 2,2-dimethyl-3-(3-Phenylureido)propyl 2-(2-(2-morpholinoethylcarbamoyl) phenoxy) acetate (6 Q): A white solid 448mg (Yield 86%). M.W: 512.59; Mol For: C₂₇H₃₆N₄O₆; LC-MS (m/z): 513.5 (M+1); ¹HNMR (400MHz, CDCl₃): δ 8.36 (s, 1H), 7.93 (s, 1H), 7.82-7.88 (m, 5H), 7.39-7.43 (t, 2H), 6.43-6.47 (m, 2H), 4.72 (s, 2H), 3.74-3.98 (m, 6H), 3.13-3.20 (m, 4H), 2.83-2.91 (d, 4H), 0.83 (s, 6H).

Preparation of Isobutyl 3-(2-(2-(2-morpholinoethylcarbamoyl) phenoxy) acetoyloxy)-2,2-dimethylpropylcarbamate (6 R): A white solid 442mg (Yield 88%). M.W: 493.59; Mol For: C₂₅H₃₉N₃O₇; LC-MS (m/z): 494.5 (M+1); ¹HNMR (400MHz, DMSO-d₆): δ 7.65 (s, 1H), 7.35-7.40 (m, 2H), 7.00-7.04 (m, 2H), 4.49-4.56 (m, 3H), 4.05-4.07 (d, 2H), 3.87-3.90 (t, 2H), 3.69-3.72 (s, 4H), 3.01-3.07 (dd, 4H), 2.53-2.55 (d, 2H), 2.40 (s, 4H), 0.87-0.91 (d, 6H), 0.73 (s, 6H).

BIOLOGICAL EVALUATION

Some of the synthesized compounds showed good antimicrobial activity inhibition. Antimicrobial screening results of the tested compounds are shown in Table 2. All the synthesized compounds showed moderate inhibitory activity and compound (6 N) showed good antifungal activity inhibition compared to other compound. Antifungal screening results of the tested compounds are shown in Table 2.

Table 2: Antibacterial and Antifungal activity data of compounds (6 L – 6 R).

Compound No.	Inhibition Zone Diameter (mm)								
	I	II	III	IV	V	VI	VII	VIII	IX
6 L	13	12	13	40	28	26	16	18	17
6 M	17	10	10	19	12	12	18	10	12
6 N	21	20	21	14	19	14	22	22	21
6 O	19	18	16	11	15	10	15	25	27
6 P	16	10	11	10	13	14	12	20	23
6 Q	18	20	22	31	23	18	22	30	28
6 R	14	22	23	13	12	15	10	10	12
Control (Solvent)	8	11	17	12	11	14	11	13	11
Ciprofloxacin	---	20	22	16	13	17	16	21	23
Fluconazole	14	---	---	---	---	---	---	---	---

Microbial Cultures Used to test antimicrobial Activity, *Fungus Culture*: I-Candida sp. *Gram Positive Bacteria*: II-Staphylococcus aureus, III-Staphylococcus albus, VIII-Streptococcus faecalis, IX- Bacillus sp. *Gram Negative Bacteria*: IV-Klebsiella pneumoniae, V-Escherichia coli, VI- Pseudomonas sp, VII- Proteus s.

CONCLUSION

In this study, the synthesis of synthesis of novel morpholine and salicylamide nucleus based derivatives (6 L – 6 R) was performed and their structures were confirmed by ¹HNMR, Mass spectroscopy techniques. In addition, the newly synthesized compounds were screened for their antibacterial and antifungal activities. Some of them were found to possess good antibacterial and antifungal activity.

ACKNOWLEDGEMENTS

The authors are thankful to management of department of chemistry, Dr. Babasaheb Ambedkar Marthawada University, Aurangabad, Maharashtra, India for providing research facilities.

REFERENCES

1. Review of morpholine and its derivatives, Merck Index, 12th ed. published by Merck & co, Whitehouse Station, NJ, 1996; 1074-5.
2. Pushpak Mizar, Bekington Myrboth. Synthesis of substituted 4-(3-alkyl-1,2,4-oxadiazol-5-ylmethyl)-3,4-dihydro-2H-1,4-benzoxazines and 4-(1H-benzimidazol-2-ylmethyl)-3,4-dihydro-2H-1,4-benzoxazines. Tetrahedron Letters. 2006; 47(44): 7823-26.

3. Satoshi Sakami, Koji Kawai, Masayuki Maeda, Takumi Aoki, Hideaki Fujii, Hiroshi Ohno et al. Design and synthesis of a metabolically stable and potent antitussive agent, a novel δ opioid receptor antagonist, TRK-851. *Bioorg Med Chem.* 2008; 16(17): 7956-67.
4. Gang Zhou, Nicolas Zorn, Pauline Ting, Robert Aslanian, Mingxiang Lin, John Cook et al. Development of Novel Benzomorpholine Class of Diacylglycerol Acyltransferase I Inhibitors. *Med Chem Lett.* 2014; 5(5): 544-49.
5. Xianhai Huang, Dmitri Pissarnitski, Hongmei Li, Theodoros Asberom, Hubert Josien, Xiaohong Zhu et al. Efficient synthesis and reaction pathway studies of novel fused morpholine oxadiazolines for use as gamma secretase modulators. *Tetrahedron Letters.* 2012; 53(47): 6451-55.
6. Madhu Chopra, VK Ahluwalia. Ane's Student Edition, Text Book of Medicinal Chemistry, 1st ed. New Delhi Published by Ane's Books Pvt. Ltd, 2008.
7. Basudeb Achari, Sukhendu BM, Pradeep Dutta, Chinmay Chowdhury. Perspectives on 1, 4-Benzodioxions, 1, 4-Benzoxazines and Their 2, 3- Dihydro Derivatives. *Synlett.* 2004; 14: 2449-67.
8. Duhalde V, Lahillie B, camou F, Pedeboscq S, pometan JP. Proper use of antibiotics: a prospective study on the use of linezolid in a French university hospital. *Pathologie biologie.* 2007; 55(10): 478-81.
9. K Marireau C, Guilloton M, kartst F. In vivo effects of fenpropimorph on the yeast *Saccharomyces cerevisiae* and determination of the molecular basis of the antifungal property. *Antimicrobial agents and chemotherapy.* 1990; 34(6): 989-93.
10. Wei Benmei, Zhang Zhiyong, Dai Zhiquan, Guan Jintao. An efficient approach for the deprotection of esters using ionic liquid as nucleophile. *Asian J Chemistry.* 2013; 25(11): 6404-06.
11. Rahmatollah Rahimi, Ensieh Gholamrezapor, Mohammad Reza Naimi-Jamal, Mahboubeh Rabbani. Oxidation of o-chloro and o-hydroxy benzyl alcohols catalyzed by copper(II) tetraphenylporphyrin nanoparticles synthesized by mixed solvent method. *Current Chem Lett.* 2012; 1(3): 101-108.
12. Maryam Mirza-Aghayan, Mahdieh Molaee Tavana, Rabah Boukherroub. Oxone/iron(II) sulfate/graphite oxide as a highly effective system for oxidation of alcohols under ultrasonic irradiation. *Tetrahedron Letters.* 2014; 55(2): 342-45
13. Luca Pignataro, Michele Boghi, Monica Civera, Stefano Carboni, Umberto Piarulli, Cesare Gennari. Rhodium-Catalyzed Asymmetric Hydrogenation of Olefins with

- PhthalaPhos, a New Class of Chiral Supramolecular Ligands. *Chemistry – A European Journal*. 2012; 18(5): 1383-1400.
14. Paul F Alewood, Michael Benn, Rolf Reinfried. Cyclizations of azidoformates to tetrahydro-1,3-oxazin-2-ones and oxazolidin-2-ones. *Canadian J Chem*. 1974; 52(24): 4083-89.
 15. Hugh W Thompson, Joseph Swistok. Enamines of 3,3-dimethylazetidide. *J Org Chem*. 1981; 46(24): 4907-11.
 16. Amal Mansour, Moshe Portnoy. Synthesis and characterization of β -aminophosphine ligands on a solid support. *J Chem Soc, Perkin Trans*. 2001; 9(1): 952-54.
 17. George W. Raiziss, LeRoy W. Clemence. 2-Sulfanilyl-aminothiazoline. *J Amer Chem Soc*. 1941; 63, 3124-6
 18. Girish Kumar Sinha, R.K. Mehra, Sharad Kumar. Synthesis of some nitrogen mustards (mannich bases). *Oriental J Chem*. 2011; 27(3): 1261-64.
 19. Angela A Salim, Kwang-Jin Cho, Lingxiao Tan, Michelle Quezada, Ernest Lacey, John F Hancock et al. Rare Streptomyces N-Formyl Amino-salicylamides Inhibit Oncogenic K-Ras. *Organic Letters*. 2014; 16(19): 5036-39.
 20. Zhijun Xin, Zhong Jia, Dian He, Jianping Liang, Lei Tao, Xuehu Li et al. Study on N-(pyridin-4-yl) salicylamides as antimycobacterial agents. *Advanced Materials Research (Durnten-Zurich, Switzerland)*. 2013; 634-638(6): 1371-75.
 21. Shaoyong Ke, Zhigang Zhang, Tong Long, Ying Liang, Ziwen Yang. Novel salicylamide derivatives incorporating neonicotinoid pharmacophore: design, synthesis, characterization, and biological evaluation. *Med Chem Research*. 2013; 22(8): 3621-28.
 22. T.W. Greene and P.G.M Green, *Protective Groups in Organic Synthesis*, 3rd Edition, published by John Wiley & Sons Inc, New York, 1999; 27-33.